Physician profile
Alfred Danielian
NPI 1205022258
$29,821.75
in general payments reported to CMS, 2019-2025
30 companies · $2,406 in 2025
The $2,406 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,205 · 2020: $3,756 · 2021: $964 · 2022: $1,767 · 2023: $5,916 · 2024: $5,808 · 2025: $2,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,200 · Food and Beverage: $6,124 · Travel and Lodging: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,200.00 |
| Food and Beverage | $6,124.19 |
| Travel and Lodging | $805.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $14,041.66 | 2019-2024 | Definity |
| Abbott Laboratories | $6,240.19 | 2019-2025 | Jot Dx, Aveir, Amplatzer Amulet |
| Boston Scientific Corporation | $3,474.62 | 2019-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $1,088.19 | 2020-2025 | |
| Amgen INC. | $756.78 | 2020-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $687.21 | 2020-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $653.22 | 2019-2025 | Evoque |
| Medtronic Vascular, INC. | $488.66 | 2019-2020 | |
| Philips North America LLC | $383.86 | 2020-2024 | (5091) Amb Mon & Diag Und |
| Cvrx, INC. | $323.64 | 2025 | Barostim Neo System |
| Abiomed | $244.11 | 2023-2025 | Impella |
| Novo Nordisk INC | $165.63 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $156.17 | 2021-2025 | |
| Penumbra, INC. | $143.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $122.84 | 2019-2023 | Xarelto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $121.28 | 2021 | |
| Celgene Corporation | $120.66 | 2024 | Camzyos |
| Merck Sharp & Dohme LLC | $106.10 | 2022-2023 | Verquvo |
| Biosense Webster, INC. | $81.13 | 2024 | Carto 3, Decanav |
| Bridgebio Pharma, INC. | $77.59 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $60.64 | 2025 | Amvuttra |
| Kowa Pharmaceuticals America, INC. | $47.88 | 2021 | |
| Atricure, INC. | $44.55 | 2021-2024 | |
| Irhythm Technologies, INC. | $36.38 | 2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.92 | 2020-2024 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $33.55 | 2022-2023 | Arcalyst |
| W. L. Gore & Associates, INC. | $25.03 | 2022 | |
| Heartflow, INC. | $22.41 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.03 | 2023 | Jardiance |
| Chiesi USA, INC. | $18.59 | 2023 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Danielian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.